相关实验视频
Updated: Sep 14, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在局部性硬化症中使用简氏激酶抑制剂:系统性文献综述
Seher Şener1, Yusuf Ziya Şener2, Ezgi Deniz Batu3
1Division of Pediatric Rheumatology, Department of Pediatrics, Adana City Training and Research Hospital, Adana, Turkiye.
雅努斯激酶 (JAK) 抑制剂显示,局部性硬皮病,特别是耐火病例的改善率为88.2%. 需要进一步的试验来确认这些JAK抑制剂的疗效和安全性.
科学领域:
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于用于局部性硬皮瘤的简氏激酶 (JAK) 抑制剂的报告越来越多.
- 本综述综合了JAK抑制剂在局部性硬化皮肤病患者中使用的已公布数据.
研究的目的:
- 审查已发表的关于JAK抑制剂用于局部性硬化皮肤症治疗的研究.
- 在这个患者群体中评估JAK抑制剂的疗效和安全性.
主要方法:
- 搜索了MEDLINE和Scopus数据库的相关文章,直到2024年8月1日.
- 包括详细介绍用JAK抑制剂治疗局部性硬化皮肤病患者的研究.
主要成果:
- 分析了涉及17名患者的11篇文章.
- 托法西替尼是最常见的JAK抑制剂 (64.7%),用于耐药性疾病 (60.7%).
- 观察到的改善率为88.2%,复发率为33.3%,副作用发生率为18.2%.
结论:
- 雅克抑制剂是耐火局部性硬化症的潜在选择.
- 需要进行更广泛的临床试验,以确定最终的疗效和安全性.
相关概念视频
The JAK-STAT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Rheumatic Heart Disease III: Medical Management

